ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.
Priya Kumthekar(Northwestern University), Nuhad K. Ibrahim(The University of Texas MD Anderson Cancer Center), Jose Carrillo(Saint John's Health Center), Carey K. Anders(Duke University), Peter Kabos(University of Colorado Anschutz Medical Campus), Manmeet S. Ahluwalia(Baptist Hospital of Miami), Katherine H. R. Tkaczuk(University of Maryland, Baltimore), David Piccioni(Center for Personalized Cancer Treatment), Santosh Kesari(Cancer Institute (WIA)), Agustin A. García(University of Southern California), Pavani Chalasani(University of Arizona), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Shou‐Ching Tang(University of Mississippi Medical Center), Shannon Puhalla(UPMC Hillman Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 22
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795